Third Opinion Trial Synopsis
This study is testing a new medicine called 211At-OKT10-B10, which is given with another drug called melphalan to treat a type of cancer called multiple myeloma. The 211At-OKT10-B10 medicine is made of a special antibody that attaches to the cancer cells and delivers a radioactive substance to kill them. Melphalan is a type of chemotherapy that can also kill cancer cells. The hope is that using both of these medicines together will be more effective in treating the cancer. This is the first phase of testing to see if the medicines are safe and what dose is best.

Trial Summary
This phase I trial studies the side effects and best dose of 211At-OKT10-B10 when given together with melphalan before a stem cell transplantation in treating patients with multiple myeloma. The radioimmunotherapy drug 211At-OKT10-B10 is a monoclonal antibody, called OKT10-B10, linked to a radioactive substance called 211At. OKT10-B10 attaches to CD38 positive cancer cells in a targeted way and delivers 211At to kill them. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving 211At-OKT10-B10 with melphalan before a stem cell transplant may kill more cancer cells.